Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Notes Payables (2021 - 2024)

Summit Therapeutics filings provide 4 years of Notes Payables readings, the most recent being $24.5 million for Q3 2024.

  • Quarterly Notes Payables fell 75.5% to $24.5 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $24.5 million through Sep 2024, down 75.5% year-over-year, with the annual reading at $19.8 million for FY2022, N/A changed from the prior year.
  • Notes Payables hit $24.5 million in Q3 2024 for Summit Therapeutics, down from $100.0 million in the prior quarter.
  • Across five years, Notes Payables topped out at $100.0 million in Q3 2023 and bottomed at $19.8 million in Q4 2022.
  • Average Notes Payables over 4 years is $59.8 million, with a median of $55.0 million recorded in 2021.
  • Peak annual rise in Notes Payables hit 75.5% in 2024, while the deepest fall reached 75.5% in 2024.
  • Summit Therapeutics' Notes Payables stood at $55.0 million in 2021, then tumbled by 64.03% to $19.8 million in 2022, then skyrocketed by 405.82% to $100.0 million in 2023, then crashed by 75.5% to $24.5 million in 2024.
  • Per Business Quant, the three most recent readings for SMMT's Notes Payables are $24.5 million (Q3 2024), $100.0 million (Q2 2024), and $100.0 million (Q3 2023).